-
公开(公告)号：US20170313766A1
公开(公告)日：2017-11-02
申请号：US15645399
申请日：2017-07-10
Applicant: AIMM THERAPEUTICS B.V.
Inventor： Hergen SPITS , Tim BEAUMONT , Mark Jeroen KWAKKENBOS , Arjen Quirinus BAKKER
IPC: C07K16/10 , G01N33/569 , A61K39/00
CPC classification number: C07K16/1018 , A61K2039/505 , C07K2317/21 , C07K2317/31 , C07K2317/33 , C07K2317/565 , C07K2317/76 , C07K2317/92 , G01N33/56983
Abstract: The invention relates to isolated, synthetic or recombinant antibodies and functional parts thereof specific for multiple influenza A virus subtypes. The invention further relates to the use of such antibodies for diagnosis of an influenza A virus infection and as a medicament and/or prophylactic agent for at least in part treating or alleviating symptoms of an influenza A virus infection.
-
公开(公告)号：US20170009205A1
公开(公告)日：2017-01-12
申请号：US15106991
申请日：2014-12-24
Applicant: AIMM THERAPEUTICS B.V.
Inventor： Pauline Maria Wilhelmina VAN HELDEN , Mark Jeroen KWAKKENBOS , Hergen SPITS , Tim BEAUMONT
IPC: C12N5/0781 , C07K16/10 , C12P21/00 , C07K16/00
CPC classification number: C12N5/0635 , C07K16/00 , C07K16/1018 , C07K2317/14 , C12N15/86 , C12N2510/00 , C12N2510/02 , C12N2510/04 , C12N2740/13045 , C12N2810/6054 , C12P21/005
Abstract: The present invention provides means and methods for producing improved ex vivo B cell cultures with a short doubling time.
Abstract translation: 本发明提供用于生产具有短加倍时间的改进的离体B细胞培养物的方法和方法。
-
公开(公告)号：US20160194382A1
公开(公告)日：2016-07-07
申请号：US15048339
申请日：2016-02-19
Applicant: AIMM THERAPEUTICS B.V.
Inventor： Tim BEAUMONT , Mark Jeroen KWAKKENBOS , Hergen SPITS , Adrianus Quirinus BAKKER
IPC: C07K16/10
CPC classification number: C07K16/1027 , C07K16/00 , C07K2317/14 , C07K2317/24 , C07K2317/56 , C07K2317/76 , C07K2317/92
Abstract: The invention provides means and methods for modulating the occurrence of somatic hypermutations in antibody producing plasmablast-like B-cells.
Abstract translation: 本发明提供用于调节抗体产生浆细胞样B细胞中体细胞超突变的发生的方法和方法。
-
公开(公告)号：US20170067880A1
公开(公告)日：2017-03-09
申请号：US15246301
申请日：2016-08-24
Applicant: Genentech, Inc. , AIMM Therapeutics B.V.
Inventor： Tim BEAUMONT , Mark Jeroen KWAKKENBOS , Eric J. BROWN , John Hiroshi MORISAKI , Wouter L.W. HAZENBOS , Sanjeev MARIATHASAN , Kimberly KAJIHARA , Yi XIA
CPC classification number: G01N33/5091 , C07K16/1271 , C07K16/1278 , C07K2317/21 , C07K2317/52 , C07K2317/56 , C07K2317/565 , C07K2317/567 , G01N33/6854 , G01N33/6893 , G01N2469/10 , G01N2800/26
Abstract: The present invention provides improved binding compounds capable of specifically binding Gram-positive bacteria. Binding compounds are provided that are fully human, enabling therapeutic applications in human individuals.
Abstract translation: 本发明提供能够特异性结合革兰氏阳性细菌的改进的结合化合物。 提供了完全人类的结合化合物，可在人类个体中实现治疗应用。
-
公开(公告)号：US20160096881A1
公开(公告)日：2016-04-07
申请号：US14956919
申请日：2015-12-02
Applicant: AIMM THERAPEUTICS B.V.
Inventor： Tim BEAUMONT , Mark Jeroen KWAKKENBOS , Hergen SPITS , Adrianus Quirinus BAKKER , Koen WAGNER
IPC: C07K16/10
CPC classification number: C07K16/1018 , C07K14/4703 , C07K14/4747 , C07K16/00 , C07K2317/21 , C07K2317/565 , C07K2317/92
Abstract: The invention provides means and methods for producing high-affinity antibodies against an antigen of interest, usually stable B-cell cultures.
Abstract translation: 本发明提供了用于产生针对感兴趣的抗原（通常是稳定的B细胞培养物）的高亲和力抗体的方法和方法。
-
Patent Agency Ranking
公开(公告)号：US20140235828A1
公开(公告)日：2014-08-21
申请号：US14103715
申请日：2013-12-11
Applicant: AIMM THERAPEUTICS B.V. , Genentech, Inc
Inventor： Tim BEAUMONT , Mark Jeroen KWAKKENBOS , Eric J. BROWN , John Hiroshi MORISAKI , Wouter L.W. HAZENBOS , Sanjeev MARIATHASAN , Kimberly KAJIHARA , Yi XIA
IPC: C07K16/12
CPC classification number: G01N33/5091 , C07K16/1271 , C07K16/1278 , C07K2317/21 , C07K2317/52 , C07K2317/56 , C07K2317/565 , C07K2317/567 , G01N33/6854 , G01N33/6893 , G01N2469/10 , G01N2800/26
Abstract: The present invention provides improved binding compounds capable of specifically binding Gram-positive bacteria. Binding compounds are provided that are fully human, enabling therapeutic applications in human individuals.
Abstract translation: 本发明提供能够特异性结合革兰氏阳性细菌的改进的结合化合物。 提供了完全人类的结合化合物，可在人类个体中实现治疗应用。
-
公开(公告)号：US20200149007A1
公开(公告)日：2020-05-14
申请号：US16575518
申请日：2019-09-19
Applicant: AIMM THERAPEUTICS B.V.
IPC: C12N5/0781 , C12P21/00 , C07K16/10 , C07K16/00 , C12N15/86
Abstract: The present invention provides means and methods for producing improved ex vivo B cell cultures with a short doubling time.
-
公开(公告)号：US20180292391A1
公开(公告)日：2018-10-11
申请号：US15900589
申请日：2018-02-20
Applicant: Genentech, Inc. , AIMM Therapeutics B.V.
Inventor： Tim BEAUMONT , Mark Jeroen KWAKKENBOS , Eric J. BROWN , John Hiroshi MORISAKI , Wouter L.W. HAZENBOS , Sanjeev MARIATHASAN , Kimberly KAJIHARA , Yi XIA
Abstract: The present invention provides improved binding compounds capable of specifically binding Gram-positive bacteria. Binding compounds are provided that are fully human, enabling therapeutic applications in human individuals.
-
公开(公告)号：US20170008952A1
公开(公告)日：2017-01-12
申请号：US15113563
申请日：2015-01-30
Applicant: AIMM THERAPEUTICS B.V
Inventor： Mark Jeroen KWAKKENBOS , Koen WAGNER , Adrianus Quirinus BAKKER
CPC classification number: C07K16/1018 , C07K16/00 , C07K2317/14 , C07K2317/21 , C07K2317/33 , C07K2317/76 , C07K2317/92 , C07K2317/94 , C12Q1/6869
Abstract: The invention provides means and methods for selecting and producing stable antibodies against an antigen of interest, using stable ex vivo B cell cultures.
Abstract translation: 本发明提供了使用稳定的离体B细胞培养物选择和产生针对感兴趣抗原的稳定抗体的方法和方法。
-
公开(公告)号：US20160168232A9
公开(公告)日：2016-06-16
申请号：US13786206
申请日：2013-03-05
Applicant: Genentech, Inc. , AIMM Therapeutics B.V.
Inventor： Tim BEAUMONT , Mark Jeroen KWAKKENBOS , Eric J. BROWN , John Hiroshi MORISAKI , Wouter L.W. HAZENBOS , Sanjeev MARIATHASAN , Kimberly KAJIHARA , Yi XIA
IPC: C07K16/12
CPC classification number: G01N33/5091 , C07K16/1271 , C07K16/1278 , C07K2317/21 , C07K2317/52 , C07K2317/56 , C07K2317/565 , C07K2317/567 , G01N33/6854 , G01N33/6893 , G01N2469/10 , G01N2800/26
Abstract: The present invention provides improved binding compounds capable of specifically binding Gram-positive bacteria. Binding compounds are provided that are fully human, enabling therapeutic applications in human individuals.
-
-
-
-
-
-
-
-
-
Search Results
11
records
(took 0.015 seconds)
